FDAnews Drug Daily Bulletin

Poor ADE Procedures Lead to Warning Letter for Elite Laboratories

Oct. 5, 2016

Elite Laboratories has been given a warning letter due to a failure to develop adequate written procedures, particularly for adverse drug experiences (ADEs).

The FDA performed an inspection of Elite’s facility in Northvale, New Jersey, between Jan. 5 and Feb. 2.

According to the letter, Elite’s Standard Operating Procedures (SOPs) fail to address how the company receives and monitors ADE information from foreign and domestic sources.

View today's stories